NovoCure Limited was downgraded from Strong Buy to Buy after its phase 3 TRIDENT trial failed to meet the primary endpoint of overall survival in newly diagnosed glioblastoma patients. Despite this setback, the company maintains growth prospects with positive phase 2 PANOVA-4 results in metastatic pancreatic cancer, an ongoing KEYNOTE D58 trial in glioblastoma, and an FDA decision expected in Q4 2026 for a brain metastases treatment. NovoCure's Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio sales, leading to an increased full-year revenue guidance of $690–$710 million. Risks include limited cash runway, potential dilution, uncertain uptake of Optune Pax, and pivotal trial outcomes that could affect future growth and valuation.
Halper Sadeh LLC is investigating whether shareholders of Simulations Plus (SLP), Huntsman Corporation (HUN), Olin Corporation (OLN), and Pulmatrix (PULM) are receiving fair deals in recent mergers and sales. The firm suspects insiders may gain finan...
LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an inducement equity award of 75,000 stock options. The options have a ten-year term, an exercise price of $32.95 per share, and vest over four...
YSX Tech Co., Ltd announced a 16.8% revenue increase to $83.5 million for fiscal year 2026, driven by a 28.8% rise in service volumes, especially in vehicle risk screening services which grew 112.1%. The company shifted focus from individual insuranc...
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have dropped below the 5% threshold, holding 4.85% as of July 8, 2026. This update is in accordance with the Danish Capital Markets Act, which requires disclosure wh...
Assassin’s Creed Black Flag Resynced, a remake of the 2013 original, sold 2 million copies on its first day, marking a strong launch for Ubisoft. The game achieved the highest concurrent player count ever for the franchise on Steam and topped Twitch ...
